Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02244047

Cytokine Profile in Children With Celiac Disease

Exploratory, Placebo-controlled Study on the Effects of Bifidobacterium Breve in Children With Celiac Disease

Sponsor: Slovenian Research Agency

Interventions Bifidobacterium breve Placebo (for Bifidobacterium breve)

Updated 6 times since 2017 Last updated: Sep 17, 2014 Started: Oct 31, 2013 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02244047, this PHASE1/PHASE2 trial focuses on Celiac Disease and remains completed. Sponsored by Slovenian Research Agency, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Mar 2019 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Slovenian Research Agency
University Medical Centre Maribor

Data source: University Medical Centre Maribor

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.